AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28212163 — intervention group
Group type: EXPERIMENTAL
Intervention: New multiple organ dysfunction syndrome (MODS)
Number of subjects: 2449
Study 25913848 — intervention group
Group type: EXPERIMENTAL
Intervention: High MUFA shake (95 g)
Number of subjects: 32
Study 25913848 — intervention group
Group type: EXPERIMENTAL
Intervention: High SFA shake (95 g)
Number of subjects: 32
Study 23680708 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy with concomitant probiotic (Bifidus infantis)
Number of subjects: 377
Study 23680708 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy with pre-treatment of probiotic (Bifidus infantis for 2 weeks)
Number of subjects: 377
Study 23680708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with concomitant probiotic (Bifidus infantis)
Number of subjects: 377
Study 23680708 — intervention group
Group type: COMPARATOR
Intervention: Traditional standard triple therapy (control group)
Number of subjects: 377
Study 21305611 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish-style snus (SS)
Number of subjects: 15
Study 21305611 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine-containing lozenge (NL)
Number of subjects: 15
Study 21305611 — intervention group
Group type: COMPARATOR
Intervention: Placebo snus (PS)
Number of subjects: 15
Study 21305611 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge (PL)
Number of subjects: 15
Study 18299468 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominoplasty
Number of subjects: 49
Study 18299468 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral breast reduction
Number of subjects: 49
Study 18299468 — intervention group
Group type: COMPARATOR
Intervention: Carpal tunnel syndrome release
Number of subjects: 49
Study 17162243 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum insulin
Number of subjects: 29
Study 17162243 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 29
Study 17162243 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 29
Study 17162243 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of highest vs lowest quartiles for each biomarker
Number of subjects: 29
Study 12975757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco abstinence
Number of subjects: 0
Study 16279825 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 60
Study 16279825 — intervention group
Group type: EXPERIMENTAL
Intervention: 550 mg naproxen sodium
Number of subjects: 60
Study 16279825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10365009 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 200 micrograms i.v. during fluid preload
Number of subjects: 50
Study 10365009 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) i.v. during fluid preload
Number of subjects: 50
Study 8704836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mattress A
Number of subjects: 100
Study 8704836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mattress B
Number of subjects: 100
Study 8704836 — intervention group
Group type: EXPERIMENTAL
Intervention: Mattress C
Number of subjects: 100
Study 8704836 — intervention group
Group type: COMPARATOR
Intervention: Control Group (other mattresses)
Number of subjects: 100
Study 2127318 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse at pH 7
Number of subjects: 11
Study 2127318 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse at pH 5.5
Number of subjects: 11
Study 2127318 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse at pH 3
Number of subjects: 11
Study 2127318 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 11
Study 7191316 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemetacin
Number of subjects: 60
Study 7191316 — intervention group
Group type: COMPARATOR
Intervention: Indometacin
Number of subjects: 60
Study 31818152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP), 4 grams daily for two weeks
Number of subjects: 21
Study 31818152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) with 20 mL propylene glycol (PG), 4 grams daily for two weeks
Number of subjects: 21
Study 30771861 — intervention group
Group type: EXPERIMENTAL
Intervention: Very optimistic patients (strongly agree)
Number of subjects: 2389
Study 30771861 — intervention group
Group type: COMPARATOR
Intervention: Neutral patients (undecided)
Number of subjects: 2389
Study 30771861 — intervention group
Group type: COMPARATOR
Intervention: Not optimistic patients (disagree or strongly disagree)
Number of subjects: 2389
Study 30771861 — intervention group
Group type: COMPARATOR
Intervention: Optimistic patients (agree)
Number of subjects: 2389
Study 29020995 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/esketamine
Number of subjects: 0
Study 29020995 — intervention group
Group type: COMPARATOR
Intervention: Propofol/alfentanil
Number of subjects: 0
Study 26093812 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT)
Number of subjects: 408
Study 26093812 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy plus radiotherapy (IC+RT)
Number of subjects: 408
Study 26093812 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 408
Study 26093812 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure-free survival
Number of subjects: 408
Study 26093812 — intervention group
Group type: EXPERIMENTAL
Intervention: Locoregional failure-free survival
Number of subjects: 408
Study 26093812 — intervention group
Group type: EXPERIMENTAL
Intervention: Distant failure-free survival
Number of subjects: 408
Study 26093812 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic factors
Number of subjects: 408
Study 23343395 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine trial (RV 144 prime-boost)
Number of subjects: 6334
Study 21208451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool Little Kids parenting group intervention (6-session program)
Number of subjects: 500
Study 21208451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 500
Study 19224281 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy (RCT)
Number of subjects: 23
Study 17424694 — intervention group
Group type: EXPERIMENTAL
Intervention: Stryker Navigation System
Number of subjects: 56
Study 17424694 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative measurements
Number of subjects: 56
Study 17424694 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative measurements
Number of subjects: 56
Study 15248832 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional radioimmunoassay (RIA)
Number of subjects: 19
Study 15248832 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 19
Study 11796805 — intervention group
Group type: EXPERIMENTAL
Intervention: Male and female condoms (group A)
Number of subjects: 149
Study 11796805 — intervention group
Group type: COMPARATOR
Intervention: Male condoms only (group B)
Number of subjects: 149
Study 11796805 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 149
Study 11796805 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condoms (group A)
Number of subjects: 149
Study 9411464 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 0
Study 9411464 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 0
Study 9411464 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer treatment duration
Number of subjects: 0
Study 9411464 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment with antidepressants
Number of subjects: 0
Study 9411464 — intervention group
Group type: COMPARATOR
Intervention: Psychological and pharmacological treatments
Number of subjects: 0
Study 8160789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of endothelin-1 (ET-1) at a rate of 1 pmol.min-1.kg-1 for 60 min
Number of subjects: 18
Study 8160789 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of endothelin-1 (ET-1)
Number of subjects: 18
Study 8160789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28987930 — intervention group
Group type: EXPERIMENTAL
Intervention: allo‐SCT
Number of subjects: 162
Study 28987930 — intervention group
Group type: COMPARATOR
Intervention: double auto‐SCT
Number of subjects: 162
Study 28987930 — intervention group
Group type: EXPERIMENTAL
Intervention: new drugs
Number of subjects: 162
Study 28987930 — intervention group
Group type: EXPERIMENTAL
Intervention: DLI
Number of subjects: 162
Study 28987930 — intervention group
Group type: EXPERIMENTAL
Intervention: allo‐SCT without DLI
Number of subjects: 162
Study 28583653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospectively ECG‐triggered high‐pitch CCTA at 70 kVp with 30mL contrast agent (protocol A)
Number of subjects: 138
Study 28583653 — intervention group
Group type: COMPARATOR
Intervention: Prospectively ECG‐triggered sequential scanning at 120 kVp and 60mL contrast medium (protocol B)
Number of subjects: 138
Study 26304935 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 7007
Study 26304935 — intervention group
Group type: COMPARATOR
Intervention: Patients without atrial fibrillation (AF)
Number of subjects: 7007
Study 24059131 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely ovulation induction with clomiphene citrate tablets at the first menstrual cycle post-operation
Number of subjects: 132
Study 24059131 — intervention group
Group type: COMPARATOR
Intervention: Expectant treatment only
Number of subjects: 132
Study 21403575 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 1 g orally 1 h before surgery
Number of subjects: 89
Study 21403575 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 800 mg orally 1 h before surgery
Number of subjects: 89
Study 21403575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 18172254 — intervention group
Group type: EXPERIMENTAL
Intervention: COX‐2 overexpression
Number of subjects: 301
Study 16983853 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening during and after surgery
Number of subjects: 60
Study 16983853 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative care (Control)
Number of subjects: 60
Study 12895316 — intervention group
Group type: EXPERIMENTAL
Intervention: UCD Cu300
Number of subjects: 2699
Study 12895316 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu220C
Number of subjects: 2699
Study 12895316 — intervention group
Group type: EXPERIMENTAL
Intervention: TCu380A
Number of subjects: 2699
Study 10740162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (15 g over a 48-hour period)
Number of subjects: 100
Study 10740162 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous dextrose solution)
Number of subjects: 100
Study 9204790 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate premedication
Number of subjects: 120
Study 9204790 — intervention group
Group type: COMPARATOR
Intervention: No glycopyrrolate premedication (Control)
Number of subjects: 120
Study 1313549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (5 mg/kg every 12 hours for 14 days, then 6 mg/kg daily for 5 days per week until day 28)
Number of subjects: 93
Study 1313549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 1313549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 93
Study 3994594 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant tone; 500 ms duration, 25 ms rise and decay, 1 s interstimulus interval
Number of subjects: 3
Study 3994594 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ms duration, 1.5 ms rise and decay, 200 ms interstimulus interval
Number of subjects: 3
Study 3994594 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone duration decreased from 100 to 5 ms
Number of subjects: 3
Study 3994594 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequencies
Number of subjects: 3
Study 3994594 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximally sensitive high frequencies
Number of subjects: 3
Study 31204556 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniocaudal approach
Number of subjects: 80
Study 31204556 — intervention group
Group type: COMPARATOR
Intervention: Caudocranial approach
Number of subjects: 80
Study 29790260 — intervention group
Group type: EXPERIMENTAL
Intervention: iv-ex9-39/ig-gluc
Number of subjects: 12
Study 29790260 — intervention group
Group type: COMPARATOR
Intervention: ig-gluc
Number of subjects: 12
Study 27557641 — intervention group
Group type: EXPERIMENTAL
Intervention: iPLAY intervention
Number of subjects: 20
Study 27557641 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 20
Study 23846381 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant (DEX implant)
Number of subjects: 289
Study 22343997 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual SICS with a superior tunnel (Group 1)
Number of subjects: 110
Study 22343997 — intervention group
Group type: COMPARATOR
Intervention: Manual SICS with a temporal tunnel (Group 2)
Number of subjects: 110
Study 20647096 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl 15 (5% sodium hypochlorite for 15 seconds)
Number of subjects: 112
Study 20647096 — intervention group
Group type: EXPERIMENTAL
Intervention: NaOCl 30 (5% sodium hypochlorite for 30 seconds)
Number of subjects: 112
Study 20647096 — intervention group
Group type: EXPERIMENTAL
Intervention: EA 15 (EndoActivator with 5% sodium hypochlorite for 15 seconds)
Number of subjects: 112
Study 20647096 — intervention group
Group type: EXPERIMENTAL
Intervention: EA 30 (EndoActivator with 5% sodium hypochlorite for 30 seconds)
Number of subjects: 112
Study 20647096 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 112
Study 20647096 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 112
Study 18765393 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg clopidogrel
Number of subjects: 166
Study 18765393 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel
Number of subjects: 166
Study 18765393 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg clopidogrel
Number of subjects: 166
Study 18765393 — intervention group
Group type: COMPARATOR
Intervention: 900 mg clopidogrel (after initial loading)
Number of subjects: 166
Study 16028466 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg daily
Number of subjects: 100
Study 16028466 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 10 mg daily
Number of subjects: 100
Study 11935036 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1087
Study 11935036 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 1087
Study 11935036 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 1087
Study 10088933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol
Number of subjects: 102
Study 10088933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 7676980 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml/sec uniphasic
Number of subjects: 150
Study 7676980 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml/sec uniphasic
Number of subjects: 150
Study 7676980 — intervention group
Group type: COMPARATOR
Intervention: 3 ml/sec biphasic
Number of subjects: 150
Study 2161058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium bromide (PPB) 0.01 mg.kg-1
Number of subjects: 0
Study 2161058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium bromide (PPB) 0.05 mg.kg-1 or 0.1 mg.kg-1
Number of subjects: 0
Study 2161058 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium bromide (PCB) 0.01 mg.kg-1
Number of subjects: 0
Study 2161058 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium bromide (PCB)
Number of subjects: 0
Study 2161058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipecuronium bromide (PPB)
Number of subjects: 0
Study 7392541 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidon for 6 weeks
Number of subjects: 12
Study 7392541 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 12
Study 30630161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU, n = 29)
Number of subjects: 58
Study 30630161 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 58
Study 29959848 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected NEX
Number of subjects: 215
Study 29959848 — intervention group
Group type: COMPARATOR
Intervention: NEX
Number of subjects: 215
Study 27453295 — intervention group
Group type: EXPERIMENTAL
Intervention: Richmond Agitation‐Sedation Scale (RASS)
Number of subjects: 996
Study 27453295 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Delirium Screening Scale (Nu‐DESC)
Number of subjects: 996
Study 27453295 — intervention group
Group type: EXPERIMENTAL
Intervention: Postanesthetic Recovery Score (PARS)
Number of subjects: 996
Study 24433412 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-session motivational and skills training program
Number of subjects: 0
Study 24433412 — intervention group
Group type: COMPARATOR
Intervention: Single-session HIV education intervention
Number of subjects: 0
Study 23168378 — intervention group
Group type: EXPERIMENTAL
Intervention: New magnetic suspension system
Number of subjects: 10
Study 23168378 — intervention group
Group type: COMPARATOR
Intervention: Pin lock system
Number of subjects: 10
Study 23168378 — intervention group
Group type: COMPARATOR
Intervention: Suction system
Number of subjects: 10
Study 20737156 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expanding metal stent or plastic stent
Number of subjects: 14
Study 18570561 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group (TG)
Number of subjects: 464
Study 18570561 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 464
Study 16092057 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 300
Study 16092057 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg/d)
Number of subjects: 300
Study 16092057 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and micronized fenofibrate (combination)
Number of subjects: 300
Study 16092057 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without MetS)
Number of subjects: 300
Study 12893114 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical, psychosocial, and combined medical-psychosocial approaches to treatment
Number of subjects: 0
Study 10553851 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.125 microg x kg(‐1) x min(‐1) (Group 2)
Number of subjects: 45
Study 10553851 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.0625 microg x kg(‐1) x min(‐1) (Group 1)
Number of subjects: 45
Study 10553851 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at 0.250 microg x kg(‐1) x min(‐1) (Group 3)
Number of subjects: 45
Study 8588415 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulm pouch (pouch reconstruction with preservation of the duodenal passage)
Number of subjects: 60
Study 8588415 — intervention group
Group type: COMPARATOR
Intervention: Hunt‐Lawrence‐Rodino pouch
Number of subjects: 60
Study 8588415 — intervention group
Group type: COMPARATOR
Intervention: Roux‐en‐Y reconstruction without pouch
Number of subjects: 60
Study 15278644 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aspirin DL‐lysine 900 mg (equivalent to aspirin 495 mg)
Number of subjects: 62
Study 15278644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 62
Study 6840159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 8
Study 6840159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg
Number of subjects: 8
Study 6840159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg
Number of subjects: 8
Study 6840159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6840159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (all doses)
Number of subjects: 8
Study 31292965 — intervention group
Group type: EXPERIMENTAL
Intervention: FM-SRP with azithromycin (AZM) (test group, n = 32)
Number of subjects: 63
Study 31292965 — intervention group
Group type: COMPARATOR
Intervention: FM-SRP without azithromycin (control group, n = 31)
Number of subjects: 63
Study 28935558 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate interruption of sedation
Number of subjects: 137
Study 28935558 — intervention group
Group type: COMPARATOR
Intervention: Usual sedation care (control group)
Number of subjects: 137
Study 25746039 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine plus Bevacizumab
Number of subjects: 37
Study 24474079 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) with physiotherapy
Number of subjects: 0
Study 24474079 — intervention group
Group type: COMPARATOR
Intervention: Chest Physiotherapy (CP)
Number of subjects: 0
Study 22545024 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor (IoL)
Number of subjects: 536
Study 22545024 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (EM)
Number of subjects: 536
Study 19364966 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (1 year after chemotherapy)
Number of subjects: 3401
Study 19364966 — intervention group
Group type: COMPARATOR
Intervention: No trastuzumab (control)
Number of subjects: 3401
Study 17331237 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care approach including Problem Solving Treatment and antidepressant treatment algorithm
Number of subjects: 40
Study 17331237 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 40
Study 15372171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoid suspension surgery
Number of subjects: 66
Study 15372171 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 66